GSK produced one vaccine in 1997 they currently produce 30 and are building more factories to produce them. The move in vaccine production has been to DNA based vaccines .
DNA vaccines are efficient at generating T-cell responses that may kill targeted cancerous cells or cells infected by the targeted virus or bacteria. *
DNA vaccines may therefore also be used as a therapeutic to treat existing disease. This capability provides the potential to treat chronic infectious diseases such as HIV and hepatitis C virus, as well as the possibility to develop therapeutic cancer vaccines.
*
DNA vaccines can potentially be developed from concept to FDA approval in eight to 10 years, compared to the up to 20-year period it took to develop the chickenpox vaccine.
*
DNA vaccines can be readily manufactured using off-the-shelf, well-proven fermentation technology.
*
DNA vaccines ? in most cases ? do not require cold storage and distribution.
It may be to target this market that schott has built a new prefill factory http://pmpnews.com/news/schott-begins-ready-fill-syringe-production-us On examination of schotts promotional material re their prefills they do not mention either auto retract or auto disable for those interested the companys web site is at http://www.us.schott.com/pharmaceutical_packaging/english/news/press.html?NID=2528
They may have a white elephant on their hands
UNI Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)